Olpha is an API and finished-dose manufacturer based in Latvia. It holds 4 active US drug master files across a filed portfolio of 4 molecules. Its filings concentrate with AIFA (IT), AEMPS (ES) and EMA. Its GMP standing is certified by EAEU_EEC, US FDA and EMA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 10 June 2024 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Latvia, Latvia | 3001672072 |
| Molecule | Regulators | Docs |
|---|---|---|
| Amantadine | US FDA | 1 |
| Anagrelide | US FDA | 1 |
| Memantine | US FDA | 1 |
| Rimantadine | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| AIFA (IT) | 203 | None |
| AEMPS (ES) | 65 | None |
| EMA | 45 | 1 |
| MHRA (UK) | 7 | None |
| UZPHARM (UZ) | 7 | 1 |
| MPA (SE) | 6 | None |
| EAEU_EEC | None | 1 |
| US FDA | None | 1 |
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Olpha comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.